-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the results of the 10-year trial of the Austrian Breast Colorectal Cancer Research Assistance Group 8 A, published online in The European Journal of Cancer, explored the results of hormone receptor-positive breast cancer patients undergoing breast preservation surgery (BCS) and continuous endocrine therapy (ET) and performing or not performing whole milk radiotherapy (WBI).
study, a total of 869 patients received ET after BCS, followed by random WBI (n - 439, 1 group) or observation (n - 430, 2 groups).
the average total dose of WBI is 50Gy (-/-10Gy), which is divided using a routine, with an additional 10 Gy (-/-2Gy) added to the tumor site.
results, after 9.89 years of mid-follow-up, 1 and 2 groups observed 10 cases and 31 cases of localized breast recurrence (IBRs), corresponding to 97.5% and 92.4% (p -0.004) respectively.
to disease-free survival (DFS) rate, it is: 94.5% (group 1) and 88.4% (2 groups), p s 0.0156.
for 10-year non-distant transfer survival (DMFS) and total survival (OS), 1 group was 96.7% and 86.6%, respectively, compared with 96.4% and 87.6% (ns) in group 2.
multiple cox regression analysis results show that WBI (risk ratio: 0.27, p.01) and tumor grading (HR:3.76, p-0.03) are independent predictive factors for IBR.
, after 10 years of mid-level follow-up, the researchers found that WBI had better local control and DFS than ET alone.
WBI and tumor grading were independent predictive factors without local recurrence.
.
